Intravenous immunoglobulin in adjuvantly treatment of severe pneumonia of infant / 中国新药与临床杂志

ABSTRACT

AIM: To study the clinical efficacy and safety of intravenous immunoglobulin (IVIG) for infant with severe pneumonia.　METHODS: Seventy patients of infant with severe pneumonia were divided into 2 groups. Patinets (n=50) of the trea- tment group (M 30, F 20; age 6 mo± s 5 mo) were treated with IVIG and conventional drugs, IVIG 400 mg*kg-1*d-1 for 3 d. Patinets (n=20) of the control group (M 12, F 8; age 7 mo±7 mo) were treated with conventional drugs.　RESULTS: The duration of fever, tachypnea, high heart rate shortened. The gasp and rales disappeared earlier. The cardiac failure recovered faster than the control group. There was significantly diffference statistically (P<0.05). The level of IgG, IgA raised after treatment. There was significantly difference statistically (P<0.01). The level of CD+3, CD+4, CD+8 after treatment also raised significantly compared with that before treatment (P<0.05). IL-6 and IL-8 after treatment reduced. There was significantly difference statistically (P<0.05).　CONCLUSION: IVIG is safe and effective drug in adjuvant treating severe pneumonia of infant, specially RSV pneumonia.